patients with allergic rhinitis, age between 18-60 years old Botulinum toxins A, Immunotherapy, Allergic Rhinitis, Vasomotor Rhinitis
Conditions
Interventions
Botulinum toxin A
Inject 10 units (1ml) each of prepared solution (BTA) over the inferior turbinates and posterior lateral nasal walls in both nasal cavities via the nasal endoscopy, overall 40 units (10U/1 point). Kee
Active Comparator Drug,Placebo Comparator Drug
Injection of Botulinum toxin A ,Injection of 0.9% normal saline
Sponsors
Faculty of Medicine of Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patient diagnosed as allergic rhinitis by clinical symptoms and confirmed by skin prick test according to ARIA guideline. 2. Age 18 years to 60 years 3. Failed to conventional pharmacological treatment (patients still have moderate to severe symptoms according to ARIA guideline or VAS at least 5) 4. Currently on immunotherapy at the maintenance dose
Exclusion criteria
Exclusion criteria: 1 Pregnancy 2 Acute or chronic rhinosinusitis 3 Previous allergy to Botox or local anesthetic agents 4 Underlying neuromuscular disorders e.g. myasthenia gravis 5 On any anti-allergic drugs within 2 weeks prior to study 6 Prior nasal surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nasal symtoms and quality of life at 4 and 8 week after intervention individual and total nasal symptoms score, RCQ-36 | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events at day 0, 4 and 8 week after intervention report | — |
Countries
Thailand
Contacts
Public ContactAvika Meksukree
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed